Text Size
37 studies found for:    " June 06, 2012":" July 06, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
" June 06, 2012":" July 06, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: darunavir (PREZISTA);   Drug: etravirine (INTELENCE);   Drug: ritonavir;   Drug: Other antiretroviral medications
2 Enrolling by invitation Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
Condition: HIV Infections
Intervention: Drug: No Investigational Product
3 Recruiting Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
Condition: HIV Infections
Interventions: Drug: Dapivirine;   Drug: Placebo
4 Recruiting Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
Conditions: HIV Infection;   Healthy
Intervention:
5 Enrolling by invitation Positive Change Agents Program-Tanzania (Evaluation)
Condition: HIV Infection
Intervention: Behavioral: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
6 Recruiting Bone Health and Vitamin D Status
Conditions: Osteopenia;   Vitamin D Deficiency;   HIV Infection
Intervention:
7 Recruiting Clinical Trial to Reduce Drinking in Women With HIV
Condition: HIV Infection
Interventions: Drug: Naltrexone;   Drug: Placebo
8 Enrolling by invitation Minority AIDS Initiative Retention and Re-Engagement Project
Condition: HIV/AIDS
Intervention: Behavioral: Enhanced Peer Intervention
9 Recruiting MARCH Central Nervous System Substudy
Condition: HIV-1 Infection
Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
10 Recruiting Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
11 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
12 Not yet recruiting Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Raltegravir
13 Recruiting Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
14 Recruiting A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)
Condition: HIV Infections
Interventions: Drug: MK-1439;   Drug: Efavirenz;   Drug: TRUVADA®
15 Completed A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: saquinavir [Invirase];   Drug: ritonavir;   Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
16 Completed A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® + Raltegravir;   Drug: MAALOX® + Raltegravir;   Drug: MAALOX® Before Raltegravir;   Drug: MAALOX® After Raltegravir
17 Recruiting Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
18 Recruiting A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Condition: HIV-1 Infection
Interventions: Drug: Darunavir;   Drug: Etravirine;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Raltegravir;   Drug: Second line ART regimens are usually based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs);   Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available;   Other: SOC adherence versus SOC+CPI adherence
19 Not yet recruiting Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
Conditions: HIV-1 Infection;   Pf Subclinical Parasitemia
Interventions: Drug: Lopinavir/ritonavir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: emtricitabine/tenofovir disoproxil fumarate;   Drug: trimethoprim/sulfamethoxazole
20 Completed Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM
Conditions: HIV Testing;   Linkage to Care
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
† Indicates status has not been verified in more than two years